- Home
- NXTC vs HOVR Comparison
NXTC vs HOVR Comparison
Compare NXTC & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- HOVR
- Stock Information
- Founded
- NXTC 2015
- HOVR 2013
- Country
- NXTC United States
- HOVR Canada
- Employees
- NXTC N/A
- HOVR N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- HOVR Blank Checks
- Sector
- NXTC Health Care
- HOVR Finance
- Exchange
- NXTC Nasdaq
- HOVR Nasdaq
- Market Cap
- NXTC 21.6M
- HOVR 20.2M
- IPO Year
- NXTC 2019
- HOVR N/A
- Fundamental
- Price
- NXTC $0.72
- HOVR $0.53
- Analyst Decision
- NXTC Strong Buy
- HOVR Strong Buy
- Analyst Count
- NXTC 2
- HOVR 1
- Target Price
- NXTC $4.00
- HOVR $2.00
- AVG Volume (30 Days)
- NXTC 61.8K
- HOVR 451.2K
- Earning Date
- NXTC 03-20-2025
- HOVR 01-14-2025
- Dividend Yield
- NXTC N/A
- HOVR N/A
- EPS Growth
- NXTC N/A
- HOVR N/A
- EPS
- NXTC N/A
- HOVR 0.36
- Revenue
- NXTC N/A
- HOVR N/A
- Revenue This Year
- NXTC N/A
- HOVR N/A
- Revenue Next Year
- NXTC N/A
- HOVR N/A
- P/E Ratio
- NXTC N/A
- HOVR $1.41
- Revenue Growth
- NXTC N/A
- HOVR N/A
- 52 Week Low
- NXTC $0.66
- HOVR $0.24
- 52 Week High
- NXTC $2.57
- HOVR $3.29
- Technical
- Relative Strength Index (RSI)
- NXTC 40.34
- HOVR 36.73
- Support Level
- NXTC $0.66
- HOVR $0.48
- Resistance Level
- NXTC $0.79
- HOVR $0.61
- Average True Range (ATR)
- NXTC 0.06
- HOVR 0.06
- MACD
- NXTC 0.00
- HOVR -0.01
- Stochastic Oscillator
- NXTC 42.21
- HOVR 22.94
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About HOVR New Horizon Aircraft Ltd.
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and aiming to build a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, Floods and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.